Advertisement


Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

ESMO Virtual Congress 2020

Advertisement

Monika K. Krzyzanowska, MD, MPH, of the Princess Margaret University Health Network, discusses study findings on remote proactive telephone-based toxicity management for patients with breast cancer receiving chemotherapy. Although the telehealth program was associated with fewer grade 3 toxicities and a slight decline in quality of life, it did not lead to fewer emergency department visits and hospitalizations (Abstract LBA87).



Related Videos

Skin Cancer
Immunotherapy

Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection

Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III melanoma, as well as a decrease in the incidence of distant and locoregional recurrence (Abstract LBA46).

Skin Cancer
Immunotherapy

Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with ipilimumab plus nivolumab (Abstract LBA45).

Prostate Cancer

Nicholas D. James, PhD, MBBS, on Prostate Cancer: Abiraterone Acetate Plus Prednisolone for Hormone-Naive Disease

Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research, London, discusses long-term STAMPEDE trial results that showed patients with metastatic, hormone-naive prostate cancer benefited from abiraterone acetate plus prednisolone in terms of overall and failure-free survival, as well as skeletal-related events (Abstract 611O).

Gynecologic Cancers

Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease

Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discusses phase II study results that showed the combination of palbociclib and letrozole, compared with placebo plus letrozole, improved progression-free survival in patients with estrogen receptor–positive advanced or recurrent endometrial cancer (Abstract LBA28).

Lung Cancer
Immunotherapy

Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, discusses results of the phase II PRINCEPS trial, which assessed, for the first time, the effect of just one injection of the immunotherapy atezolizumab before surgery in patients with resectable non–small cell lung cancer (Abstract 1215O).

Advertisement

Advertisement




Advertisement